Table.
Clinical and Demographic Data *
| Artisanal-CBD (n = 11) | Pharmaceutical-CBD (n = 31) | |
|---|---|---|
| Age, median (IQR), yr | 8 (5–13.3) | 9.5 (7–15.3) |
| F/U, median (IQR), mo | 7.8 (4.6–45) | 14 (4–21) |
| Sex, n (%) | ||
| Male | 4 (36) | 14 (45) |
| Female | 7 (64) | 17 (55) |
| Additional ASM | ||
| Median (IQR) | 2 (1–3) | 3 (2–3) |
| Using CLB, n (%) | 6 (55) | 6 (26) |
| Using VPA, n (%) | 2 (18) | 4 (17) |
| Using Keto, n (%) | 1 (9) | 2 (6) |
| Diagnosis, n (%) | ||
| LGS | 3 (27) | 13 (42) |
| Dravet | 1 (9) | 2 (5) |
| GGE | 2 (18) | 9 (29) |
| DEE | 2 (18) | 6 (19) |
| Focal | 3 (27) | 1 (3) |
| Seizure outcome | ||
| Overall, n (%) | 0 (−50 to 50) | −50 (−90 to 0) |
| 50% RR | 36 | 45 |
ASM, antiseizure medication; CBD, cannabidiol; CLB, clobazam; DEE, developmental and epileptic encephalopathy; F/U, follow-up; GGE, genetic generalized epilepsy; Keto, ketogenic diet; LGS, Lennox-Gastaut syndrome; VPA, valproic acid; 50% RR, 50% responder rate
* All values expressed as n (%) or median (IQR).